Novozymes A/S (OTCMKTS:NVZMY) Upgraded at Kepler Capital Markets

Kepler Capital Markets upgraded shares of Novozymes A/S (OTCMKTS:NVZMYFree Report) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

A number of other research firms also recently issued reports on NVZMY. Rothschild & Co Redburn raised shares of Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Zacks Research downgraded shares of Novozymes A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Novozymes A/S presently has an average rating of “Buy”.

Check Out Our Latest Report on NVZMY

Novozymes A/S Stock Down 1.1%

NVZMY opened at $58.59 on Wednesday. The firm has a 50 day moving average price of $58.40 and a 200 day moving average price of $60.93. The company has a market cap of $24.29 billion, a PE ratio of 39.59, a price-to-earnings-growth ratio of 1.11 and a beta of 0.98. Novozymes A/S has a 1 year low of $49.90 and a 1 year high of $75.99. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.44 and a current ratio of 0.72.

Novozymes A/S (OTCMKTS:NVZMYGet Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a return on equity of 6.57% and a net margin of 14.22%. Sell-side analysts expect that Novozymes A/S will post 2.43 earnings per share for the current year.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

Featured Stories

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.